Krystal Total Current Liabilities from 2010 to 2025
| KRYS Stock | USD 156.07 0.23 0.15% |
Total Current Liabilities | First Reported 2016-12-31 | Previous Quarter 71.9 M | Current Value 89.5 M | Quarterly Volatility 22.8 M |
Check Krystal Biotech financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Krystal Biotech's main balance sheet or income statement drivers, such as Net Interest Income of 27.3 M, Interest Income of 27.3 M or Depreciation And Amortization of 6 M, as well as many indicators such as Price To Sales Ratio of 72.59, Dividend Yield of 0.0 or PTB Ratio of 4.73. Krystal financial statements analysis is a perfect complement when working with Krystal Biotech Valuation or Volatility modules.
Krystal | Total Current Liabilities |
Latest Krystal Biotech's Total Current Liabilities Growth Pattern
Below is the plot of the Total Current Liabilities of Krystal Biotech over the last few years. Total Current Liabilities is an item on Krystal Biotech balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Krystal Biotech are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. It is the total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations. Krystal Biotech's Total Current Liabilities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Krystal Biotech's overall financial position and show how it may be relating to other accounts over time.
| Total Current Liabilities | 10 Years Trend |
|
Total Current Liabilities |
| Timeline |
Krystal Total Current Liabilities Regression Statistics
| Arithmetic Mean | 11,750,757 | |
| Geometric Mean | 991,157 | |
| Coefficient Of Variation | 133.34 | |
| Mean Deviation | 13,830,446 | |
| Median | 2,596,000 | |
| Standard Deviation | 15,668,898 | |
| Sample Variance | 245.5T | |
| Range | 39.9M | |
| R-Value | 0.89 | |
| Mean Square Error | 56.2T | |
| R-Squared | 0.79 | |
| Slope | 2,918,334 | |
| Total Sum of Squares | 3682.7T |
Krystal Total Current Liabilities History
About Krystal Biotech Financial Statements
Krystal Biotech shareholders use historical fundamental indicators, such as Total Current Liabilities, to determine how well the company is positioned to perform in the future. Although Krystal Biotech investors may analyze each financial statement separately, they are all interrelated. The changes in Krystal Biotech's assets and liabilities, for example, are also reflected in the revenues and expenses on on Krystal Biotech's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Total Current Liabilities | 38.1 M | 40 M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Krystal Stock Analysis
When running Krystal Biotech's price analysis, check to measure Krystal Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Krystal Biotech is operating at the current time. Most of Krystal Biotech's value examination focuses on studying past and present price action to predict the probability of Krystal Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Krystal Biotech's price. Additionally, you may evaluate how the addition of Krystal Biotech to your portfolios can decrease your overall portfolio volatility.